Emerging drug targets for pain treatment.
Pain is a global health challenge. For decades, we have been primarily relying upon opioids and nonsteroidal anti-inflammatory drugs (NSAIDs) for pain management. However, adverse effects related to opioid and NSAID use are severe and often lead to forced drug discontinuation and inadequate pain relief. Despite decades of research, currently available pharmacotherapies for pain still fall short of clinical needs. Fortunately, with our increased understanding of the neurobiology and pathophysiology of pain, new drug targets have been emerging, which may lead to novel therapeutic strategies. This perspective will briefly review the theoretical development and experimental evidence of four emerging drug targets for pain treatment: transient receptor potential ankyrin (TRPA) 1 channel, cannabinoid CB(2) receptors, GABA(A) subtype receptors, and imidazoline I(2) receptors. Sustained efforts on these novel drug targets will increase the appreciation for these targets and expedite the development of lead compounds to reach clinical stage, which will undoubtedly strengthen our pharmacotherapeutic armaments against various debilitating painful conditions.
Department of Pharmacology and Toxicology, University at Buffalo, State University of New York, Buffalo, NY 14214, USA. junxuli@buffalo.edu
Jun-Xu
JX
Li
Yanan
Y
Zhang
D000700:Analgesics / Q000009:adverse effects / Q000494:pharmacology*; D000701:Analgesics, Opioid / Q000009:adverse effects / Q000494:pharmacology; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000494:pharmacology; D016503:Drug Delivery Systems; D015195:Drug Design; D014943:Global Health; D006801:Humans; D010146:Pain / Q000188:drug therapy* / Q000503:physiopathology
D000700:Analgesics; D000701:Analgesics, Opioid; D000894:Anti-Inflammatory Agents, Non-Steroidal